Prospect

Today on TAP: Americans, it turns out, want to revive domestic manufacturing. Advantage, Biden.

The former president deserves every legal penalty that can possibly be imposed.

Deregulation has rendered station ownership caps meaningless. But a federal antitrust case and a new FCC majority offer one last chance to unwind broadcast consolidation.

Workers are celebrating minimum-wage increases around the country, but the new frontier is already creeping toward $20.

Environmentalists question the sustainability commitments made by Denver-based Civitas Resources.

Today on TAP: Must America go down with the Biden campaign?

He argues that the 14th Amendment allows him, a naturalized citizen, to serve as president. There’s a larger question at stake here about perfecting our Constitution.

And it’ll be fine, so long as Biden doesn’t get impeached, they implied.

The right’s long and all-too-unanswered war on liberal institutions claims a big one.

Today on TAP: An American general’s prescription for how we should have fought in Vietnam has been realized in Israel’s war on Gaza.

The door plug that ripped off an Alaska Airlines plane only exists because of cost-cutting production techniques to facilitate cramming more passengers into the cabin.

Mike Johnson got almost precisely the same appropriations deal as Kevin McCarthy.

A ferocious advocate and a kind friend

Today on TAP: The usually public-minded commission is on the verge of permitting a new Bitcoin gold rush.

A new book documents the lost (and pro-Democratic) world of Pennsylvania steelworkers and how it became Republican.

Demetrios Kouzoukas’s nomination battle offers the perfect opportunity for Democrats to prove themselves to voters.

Everyone thought these companies couldn’t handle the end of the repayment pause. Everyone was right.

They just want to sustain the image of an immigration crisis.

A would-be dictator does not need help from the opposition making his legal arguments.

California is about to start developing and manufacturing insulin. But is the state too tied up with nonprofit Civica Rx, rather than building its own capacity?